The genetic causes of a group of related infant cancers have been discovered by scientists. Whole genome sequencing of tumours revealed mutations which are targetable by existing drugs used to treat lung cancer and melanoma. The results have implications for clinical practice and the diagnosis of rare cancers in infants, and could lead to new, targeted treatment options for these children.